Expression profile of SARS-CoV-2 cellular entry proteins in normal oral mucosa and oral squamous cell carcinoma.
Angiotensin-Converting Enzyme 2
/ genetics
COVID-19
/ genetics
Carcinoma, Squamous Cell
/ genetics
Furin
/ genetics
Gene Expression
/ genetics
Head and Neck Neoplasms
Humans
Mouth Mucosa
Mouth Neoplasms
/ genetics
Mucous Membrane
/ pathology
RNA, Messenger
/ genetics
SARS-CoV-2
/ genetics
Serine Endopeptidases
/ genetics
Squamous Cell Carcinoma of Head and Neck
Tongue
/ metabolism
ACE2
COVID-19
expression
head cancer
microarray
neck cancer
oral cancer
tongue
Journal
Clinical and experimental dental research
ISSN: 2057-4347
Titre abrégé: Clin Exp Dent Res
Pays: United States
ID NLM: 101692332
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
revised:
29
04
2021
received:
09
09
2020
accepted:
02
10
2021
pubmed:
3
11
2021
medline:
31
3
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Besides angiotensin converting enzyme 2 (ACE2), an active involvement of proteases (FURIN and/or TMPRSS2) is important for cellular entry of SARS-CoV-2. Therefore, a simultaneous expression profiling of entry proteins in a tissue might provide a better risk assessment of SARS-CoV-2 infection as compared to individual proteins. In an attempt to understand the relative susceptibility of oral squamous cell carcinoma (OSCC) lesions as compared to the normal oral mucosa (NOM) for SARS-CoV-2 attachment/entry, this study examined the mRNA and protein expression profiles of ACE2, FURIN, and TMPRSS2 in the corresponding tissues using public transcriptomic and proteomics datasets. Public transcriptomic and proteomics datasets (the Cancer Genome Atlas (TCGA)/the Genotype-Tissue Expression (GTEx), the Human Protein Atlas (HPA), and two independent microarray datasets) were used to examine the expression profiles of ACE2, TMPRSS2 and FURIN in NOM and OSCC. ACE2, TMPRSS2, and FURIN mRNAs were detected in NOM, however, at lower levels as compared to other body tissues. Except for moderate up-regulation of FURIN, expression levels of ACE2 and TMPRSS2 mRNA were unchanged/down-regulated in OSCC as compared to the NOM. These results indicate that NOM may serve as a possible site for SARS-CoV-2 attachment, however, to a lesser extent as compared to organs with higher expression levels of the SARS-CoV-2 entry proteins. However, the evidence is lacking to suggest that expression status of entry proteins predisposes OSCC lesions to additional risk for SARS-CoV-2 attachment/entry as compared to NOM.
Identifiants
pubmed: 34726347
doi: 10.1002/cre2.510
pmc: PMC8653086
doi:
Substances chimiques
RNA, Messenger
0
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Serine Endopeptidases
EC 3.4.21.-
TMPRSS2 protein, human
EC 3.4.21.-
FURIN protein, human
EC 3.4.21.75
Furin
EC 3.4.21.75
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-122Subventions
Organisme : Faculty of Dentistry, University of Oslo
Informations de copyright
© 2021 The Authors. Clinical and Experimental Dental Research published by John Wiley & Sons Ltd.
Références
Clin Exp Dent Res. 2022 Feb;8(1):117-122
pubmed: 34726347
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2152-62
pubmed: 18669583
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11727-11734
pubmed: 32376634
Nat Rev Microbiol. 2009 Jun;7(6):439-50
pubmed: 19430490
Mol Cancer. 2020 Apr 28;19(1):80
pubmed: 32345328
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
J Dent Res. 2020 Sep;99(10):1120-1121
pubmed: 32479133
Nature. 2014 Mar 27;507(7493):462-70
pubmed: 24670764
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Clin Cancer Res. 2004 Jul 1;10(13):4480-8
pubmed: 15240540
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
PLoS One. 2012;7(4):e35276
pubmed: 22530001
Mol Cell. 2020 May 21;78(4):779-784.e5
pubmed: 32362314
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Oncol. 2020 Jul;21(7):893-903
pubmed: 32479790
Nat Commun. 2017 Oct 20;8(1):1077
pubmed: 29057876
Med Hypotheses. 2020 Nov;144:109987
pubmed: 32562913
Science. 2015 May 8;348(6235):648-60
pubmed: 25954001
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336